Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofrogliptin biweekly versus linagliptin daily add-on to metformin + dapagliflozin in type 2 diabetes
ChiCTR2400089745Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Cofrogliptin add-on group with Linagliptin active-control group (2 arms). Primary endpoint: Change in HbA1c from baseline to week 24. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
cofrogliptinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400089745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089745.